[Quantitative viremia and p24 antigenemia in short-term follow-up of the treatment with zidovudine in twenty HIV infected patients]. 1993

C Tamalet, and J Puel, and H Fleury, and F Ferchal, and H Agut, and F Brun-Vezinet, and G Botti, and C Rouzioux
Hôpital Timone, bd Jean-Moulin, Marseille, France.

The authors emphasize the interest of detecting HIV p24 antigen after immune complexes dissociation as well as changes in cellular viremia titers in the therapeutic follow-up of HIV infected patients. A significant decline of cell virus titers was found in 4-8 weeks among 13 of 20 zidovudine treated patients. A significant decrease of immune complexes dissociated p24 antigenemia was noted in 11 out of 17 patients.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000936 Antigen-Antibody Complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES. Immune Complex,Antigen-Antibody Complexes,Immune Complexes,Antigen Antibody Complex,Antigen Antibody Complexes,Complex, Antigen-Antibody,Complex, Immune,Complexes, Antigen-Antibody,Complexes, Immune
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016655 HIV Core Protein p24 A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by ELISA and Western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines. HIV Major Core Protein p24,HIV gag Gene Product p24,HIV p24 Antigen,gag Protein p24, HIV,p24(HIV),HIV Protein p24,HTLV-III p24,p24 protein, Human Immunodeficiency Virus,HTLV III p24,p24 Antigen, HIV,p24, HIV Protein,p24, HTLV-III

Related Publications

C Tamalet, and J Puel, and H Fleury, and F Ferchal, and H Agut, and F Brun-Vezinet, and G Botti, and C Rouzioux
October 2002, Fundamental & clinical pharmacology,
C Tamalet, and J Puel, and H Fleury, and F Ferchal, and H Agut, and F Brun-Vezinet, and G Botti, and C Rouzioux
January 1990, Scandinavian journal of infectious diseases,
C Tamalet, and J Puel, and H Fleury, and F Ferchal, and H Agut, and F Brun-Vezinet, and G Botti, and C Rouzioux
December 1993, AIDS research and human retroviruses,
C Tamalet, and J Puel, and H Fleury, and F Ferchal, and H Agut, and F Brun-Vezinet, and G Botti, and C Rouzioux
May 1995, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
C Tamalet, and J Puel, and H Fleury, and F Ferchal, and H Agut, and F Brun-Vezinet, and G Botti, and C Rouzioux
February 1988, Annals of internal medicine,
C Tamalet, and J Puel, and H Fleury, and F Ferchal, and H Agut, and F Brun-Vezinet, and G Botti, and C Rouzioux
June 1988, AIDS (London, England),
C Tamalet, and J Puel, and H Fleury, and F Ferchal, and H Agut, and F Brun-Vezinet, and G Botti, and C Rouzioux
May 1996, AIDS research and human retroviruses,
C Tamalet, and J Puel, and H Fleury, and F Ferchal, and H Agut, and F Brun-Vezinet, and G Botti, and C Rouzioux
January 1991, Contributions to nephrology,
C Tamalet, and J Puel, and H Fleury, and F Ferchal, and H Agut, and F Brun-Vezinet, and G Botti, and C Rouzioux
February 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
C Tamalet, and J Puel, and H Fleury, and F Ferchal, and H Agut, and F Brun-Vezinet, and G Botti, and C Rouzioux
February 1998, Journal of neurovirology,
Copied contents to your clipboard!